27th April 2017

Roche Diagnostics UK hosts meeting with global colleagues and healthcare leaders to discuss the latest developments in innovation

LONDON, UK (27 April 2017) – Roche Diagnostics UK welcomed global colleagues and
thirty healthcare leaders from the UK and Ireland today (27 April), to discuss the adoption of
new technologies in the health system at the first ever Roche Diagnostics R&D Insights
meeting.

Following the meeting, Chris Hudson, Director of Healthcare Development and Strategic
Services at Roche Diagnostics, said:

“Roche Diagnostics prides itself on its positive working relationship with healthcare leaders
in the UK and Ireland, and we have been delighted to welcome a number of them to meet
with colleagues from across the world. Our two day Insights meeting has showcased some of
the latest developments in technology and how we are now working with health services to
deliver these innovations in what is an exciting time for the life sciences sector. We call on
the Government to work with the NHS and industry to make sure that all eligible patients are
able to have swift access to innovative medicines and diagnostics.”

ENDS

For more details please contact: roche@fourcommunications.com

NOTE TO EDITORS

Photos from the event are available from: roche@fourcommunications.com

ABOUT ROCHE
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to
improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under
one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit
the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in
oncology, immunology, infectious diseases, ophthalmology and diseases of the central
nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat
diseases and make a sustainable contribution to society. The company also aims to improve
patient access to medical innovations by working with all relevant stakeholders. Twenty-nine
medicines developed by Roche are included in the World Health Organization Model Lists of
Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.
Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals,
Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability
Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in
2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9
billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a
wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.